Navigation Links
Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Date:6/9/2008

MOUNTAIN VIEW, Calif., June 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today preliminary results from its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. The study did not meet its two primary endpoints, which were the effect of AZ-002 on the incidence of a doxapram-induced panic attack and the effect of AZ-002 on the duration of a doxapram-induced panic attack, both as compared with placebo. There were no serious adverse events in the clinical trial, and AZ-002 was safe and well tolerated in the study patient population. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital LLC in 2006.

The Company also announced today, in a separate news release, that it has completed enrollment of its first Phase 3 clinical trial with AZ-004 (Staccato loxapine)for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza will host an investor conference call to discuss today's announcements on Monday, June 9, 2008 at 5:15 p.m. Eastern Time.

"The failure to reach statistical significance on the primary endpoints is disappointing, but this proof-of-concept clinical trial was designed to capture data and measurements for a number of clinical parameters in this clinical setting," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza and chairman of the Symphony Allegro Development Board. "There is no FDA-approved therapy for the acute treatment of a panic attack or an established clinical development pathway for this potential new indication. We plan to work with our colleagues at Symphony Allegro and our ext
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
2. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
3. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
6. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
7. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
8. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
11. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... 22, 2014 AVACEN Medical announced today that ... (k) OTC clearance by the U.S. Food and Drug ... marketed over the Internet for: the temporary relief ... minor strains and sprains . Logo - ... (MSRP $2495) is a sophisticated medical device incorporating over ...
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... and Chief Executive Officer, has been elected to the ... Steven G. Anderson , Executive Chairman of ... proven to be an excellent leader who is well ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... A new report criticizes the US Drug Enforcement ... addictive medications without a valid prescription requirement. ... , analyzes the DEA,s implementation of the Ryan Haight Online ... named after an 18-year old who died after purchasing Vicodin ...
... VIEW, Calif., June 8, 2011 Edison Pharmaceuticals, ... Drug Administration has granted orphan drug designation to ... diseases. Today, these mitochondrial diseases affect an estimated ... passed in 1982, provides incentives for companies to ...
Cached Medicine Technology:Report Criticizes DEA for Failing to Address Online Pharmacy Problem 2Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation 2
(Date:10/22/2014)... Weight Your Body’s Way , In a world where a ... certainly can be difficult to choose the right weight loss ... doing it the healthy way? Set aside the fads and ... exercise regularly, and choose foods with the most nutritional benefits. ... to exercise more and eat less. Despite the number of ...
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... Ebola while working for NBC News in Liberia has ... isolation unit at Nebraska Medical Center in Omaha, where he had ... A blood test confirmed by the U.S. Centers for Disease ... to Providence, R.I., NBC News reported Tuesday night. ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... leading cause of disability among adults. As the population ages, ... and public health toll of this chronic, crippling joint disease. ... diagnosis, moderate exercise is one of the most effective ways ... of the knee and hip. , ...
... disease is the major cause of mortality in patients ... with Duchenne muscular dystrophy and approximately 70 % of ... two common forms of muscular dystrophy caused by defects ... with dilated cardiomyopathy (DCM), heart failure and premature death. ...
... transient episodes of bilateral muscle weakness with areflexia ... to narcolepsy. Cataplexy is diagnosed based on clinical ... recently but their usefulness has been limited because ... , ,Used effectively even these screening tests ...
... most often begins in infancy. Sleep disturbances in children with ... not only impact the afflicted child but may // also ... conducted with the aim to evaluate sleep disturbance and co ... association between sleep characteristics and features of the disease. , ...
... researchers have known that high density lipoproteins, commonly called ... from certain parasites. // The mechanism however remained unclear ... ,Human HDLs work by serving as a platform ... proteins that combine to create a super-toxic antimicrobial. ,The ...
... exposure to polluted air is associated with a significant increase ... blood clot travels to the brain. ,Researchers examined the ... separate cities, and found that risk of hospitalization for ischemic ... levels of air pollution, compared with low-air pollution days. ...
Cached Medicine News:Health News:Exercise Can Strenghten Knee Cartilage 2Health News:Air pollution found to increase risk of ischemic stroke 2
... patients with a diseased heart, the only therapy solution ... transplant. However, donor organs are not always readily available. ... are on the waiting list for a donor organ. ... save the life of a patient. On the one ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay is ... Specialty System. The Nichols Advantage® 25-Hydroxyvitamin D ... of 25-,hydroxyvitamin D (25-OH-D) and other hydroxylated ... plasma to be used as an aid ...
... The CoaguChek Pro is a ... of the coagulation parameters PT, APTT, ... professional use in hospitals and medical ... e.g., in cardiac catheterization laboratories, and ...
Medicine Products: